Notably, when the standard pGT141GmCSF-b7.1 therapy was compared with pEEVGmCSF-b7.1, the percentage of CD19+ (P<0.001), DX5+/CD3+ (P<0.01), CD11c+ (P<0.001) and CD8+ (P<0.001) cells were all significantly greater, indicating that pEEVGmCSF-b7.1 recruits a superior immune recruitment locally at the tumour site. This evidence concerns the gene CD8A and neoplasm.